See also Editorial by Peter, Myles
W. Korte (1), M. Cattaneo (2), P.-G. Chassot (3), S. Eichinger (4), C. von Heymann (5), N. Hofmann (6), H. Rickli (7), M. Spannagl (8), B. Ziegler (9), F. Verheugt (10), K. Huber (11)
(1) Center for Laboratory Medicine, Kantonsspital St. Gallen, Switzerland; (2) Medicina 3, Ospedale San Paolo, Department of Medicine, Surgery and Dentistry, Università degli Studi di Milano, Milan, Italy; (3) Departement of Anesthesiology, University Hospital Lausanne, Switzerland; (4) Department of Medicine I, Division of Hematology, Medical University of Vienna, Austria; (5) Department of Anesthesiology and Intensive Care, Charité-Universitätsmedizin Berlin, Germany; (6) Department of Anesthesiology, Diakonissen-Krankenhaus Salzburg, Austria; (7) Division of Cardiology, Kantonsspital St. Gallen, Switzerland; (8) Division of Haemostaseology, University of Munich, Germany; (9) Department of Anesthesiology, Landeskliniken Salzburg, Austria; (10) Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; (11) 3rd Department of Medicine, Wilhelminenhospital, Vienna, Austria
An increasing number of patients suffering from cardiovascular disease, especially coronary artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major adverse events. Unfortunately, there are no specific, widely accepted recommendations for the perioperative management of patients receiving antiplatelet therapy. Therefore, members of the Perioperative Haemostasis Group of the Society on Thrombosis and Haemostasis Research (GTH), the Perioperative Coagulation Group of the Austrian Society for Anesthesiology, Reanimation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society of Cardiology (ESC) have created this consensus position paper to provide clear recommendations on the perioperative use of anti-platelet agents (specifically with semi-urgent and urgent surgery), strongly supporting a multidisciplinary approach to optimize the treatment of individual patients with coronary artery disease who need major cardiac and non-cardiac surgery. With planned surgery, drug eluting stents (DES) should not be used unless surgery can be delayed for ≥12 months after DES implantation. If surgery cannot be delayed, surgical revascularisation, bare-metal stents or pure balloon angioplasty should be considered. During ongoing antiplatelet therapy, elective surgery should be delayed for the recommended duration of treatment. In patients with semi-urgent surgery, the decision to prematurely stop one or both antiplatelet agents (at least 5 days pre-operatively) has to be taken after multidisciplinary consultation, evaluating the individual thrombotic and bleeding risk. Urgently needed surgery has to take place under full antiplatelet therapy despite the increased bleeding risk. A multidisciplinary approach for optimal antithrombotic and haemostatic patient management is thus mandatory.
Atherosclerosis, surgery, atherothrombosis, coronary syndrome, Antiplatelet agents
Andreas E. May, Tobias Geisler, Meinrad Gawaz
Thromb Haemost 2008 99 3: 487-493
Christian Schulz1, Ildiko Konrad1, Susanne Sauer1, Lena Orschiedt1, Maria Koellnberger1, Reinhard Lorenz2, Ulrich Walter3, Steffen Massberg1,4
Thromb Haemost 2008 99 1: 190-195
B. Hechler (1), C. Gachet (1)
Thromb Haemost 2011 105 Suppl. 1: S3-S12
Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...
Atrial fibrillation is the commonest heart rhythm condition. Women with atrial fibrillation...
Prothrombin complex concentrates (PCC) can rapidly normalise prolonged prothrombin time, induced...